Stockreport

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

aTyr Pharma, Inc.  (ATYR) 
PDF Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary [Read more]